Alnylam Pharmaceuticals (ALNY) Current Deferred Revenue (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has reported Current Deferred Revenue for 18 consecutive years, with $4.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Current Deferred Revenue fell 73.38% year-over-year to $4.0 million; the trailing twelve-month figure through Jun 2026 stood at $4.0 million (down 73.38% YoY), and the FY2025 full-year result was $4.8 million, down 91.27% from the prior year.
• Current Deferred Revenue improved to $4.0 million in Q2 2026 per ALNY's latest filing, from $3.2 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $290.8 million in Q4 2023 and bottomed at $2.5 million in Q3 2025.
• Historically, Current Deferred Revenue has averaged $78.6 million across 5 years, with a median of $62.2 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Current Deferred Revenue surged 114.7% in 2024, then plunged 96.42% in 2025.
• Over 5 years, Current Deferred Revenue stood at $235.5 million in 2022, then advanced by 23.45% to $290.8 million in 2023, then tumbled by 80.92% to $55.5 million in 2024, then sank by 91.27% to $4.8 million in 2025, then fell by 17.15% to $4.0 million in 2026.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $4.0 million, $3.2 million, and $4.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.